Hyderabad: Aragen Life Sciences (Aragen), a leading Contract Research and Development Organization (CRO), and FAR Biotech (FAR), a US-based, AI-driven, computational drug discovery company, have announced a collaboration to advance preclinical programs in neurodegeneration.
As part of the collaboration, Aragen will deploy its proven experimental discovery platform to help FAR advance its small molecule program towards an important milestone in neurodegeneration.
Dr. Ramesh Subramanian, Chief Commercial Officer, Aragen said, “We look forward to initiating our collaboration with FAR Biotech to advance its pipeline of therapeutic candidates. Aragen has developed strong capabilities in providing integrated drug discovery (IDD) solutions to its customers to accelerate their discovery programs and this collaboration marks an inflection point for our IDD vertical.”
Dr. Simon Haydar, SVP & Head of Integrated Drug Discovery, Aragen, added, “We are encouraged…
